Skip Ribbon Commands
Skip to main content

Assoc Prof Chua Lee Kiang Melvin

Dr Chua Lee Kiang Melvin from National Cancer Centre Singapore

Assoc Prof Chua Lee Kiang Melvin

MBBS (London), FRCR (Clinical Oncology), PhD (Cancer & Radiation Biology)

Senior Consultant

National Cancer Centre Singapore

Specialty: Radiation Oncology

Sub-specialties: Head & Neck, Neuro-Oncology, Uro-Oncology

Conditions Treated by this Doctor:
Head and Neck Cancer, Nasopharyngeal Cancer (Nose Cancer), Neuro-oncology, Uro-Oncology.

Clinical Appointments

  • Senior Consultant Division of Radiation Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Associate Professor


​Dr Melvin Chua is a Clinician-Scientist at the National Cancer Centre Singapore, and Principal Investigator of the Tan Chin Tuan Laboratory of Optical Imaging, Photodynamic and Proton Beam Therapy – Precision Radiation Oncology Programme, Division of Radiation Oncology. His research is supported by the NMRC Clinician-scientist award, and is focused on discovery and translational cancer genomics, and the development of biomarker-directed clinical trials in nasopharyngeal (NPC) and prostate cancers.

He graduated from the Yong Loo Lin School of Medicine, National University Singapore in 2002. He obtained his Fellowship in Clinical Oncology from the Royal College of Radiologists, and his Doctorate from the University College London in 2013. He later completed post-doctoral Clinician-scientist fellowships at the Mount Vernon Cancer Centre, UK, and the Princess Margaret Cancer Center, Toronto.

Dr Chua is a KOL on NPC and prostate cancer, and he has been invited to speak at more than 100 international meetings. He is also on the scientific advisory board for the NPC Guangzhou-Singapore Trial Network and a board member on the Head Neck Cancer International Group (HNCIG).

His other academic activities include his roles as the Associate Senior Editor of the International Journal of Radiation Oncology Biology Physics – Official journal of the American Society of Radiation Oncology and Editor-in-Chief, Annals of Nasopharynx Cancer. He also serves on the International Education Steering Group and the Asia-Pacific Regional Council of the American Society of Clinical Oncology (ASCO). He has published over 80 peer-reviewed papers, with a H-index of 22, including highly cited articles in the New England Journal of Medicine, Lancet, Nature, Cell, Journal of Clinical Oncology and JAMA Oncology.


  • 2013 Ph.D, University College London
  • 2013 F.R.C.R (Clinical Oncology), The Royal College of Radiologists, UK
  • 2002 M.B.B.S., National University of Singapore

Professional Appointments and Committee Memberships

  • Co-Chairman, NCCS Research Biosafety Committee (2019-Present)
  • Board Member, Head Neck Cancer International Group (HNCIG) (2019 – Present)
  • Member, American Society of Clinical Oncology – International Regional Council (2019 – Present)
  • Member, American Society of Clinical Oncology – International Education Steering Group (IESG) (2019-2020)
  • EXCO member, Singapore Society of Oncology (2018 – Present)
  • Member, Grant Monitoring Committee of NCCS Research Fund (2018 – Present)
  • Co-Chair, NCCS Biennial Research Book Committee (2018)
  • Member, Clinical Service Line Discussion Group for Head and Neck, Genitourinary, and Nasopharynx Cancers, NCCS (2017 – Present)
  • Member, American Society of Clinical Oncology - Multidisciplinary Cancer Management Course (MCMC) Working Group (2017-2020)
  • Trustee, Alice’s Arc (Children’s Cancer Charity, UK; Charity Commission No. 1164253) (2016 – Present)


  • Manpower Development Plan Leadership Award, MOH Health (2020)
  • Clinician Scientist (INV) Award, National Medical Research Council (2018)
  • ASCO Merit Award, American Society of Clinical Oncology (2013, 2016, 2017)
  • Ferring Singapore Innovation Award (2017)
  • Sanofi Research Award, Canadian Urologic Oncology Group (2015)
  • Transition Award for Clinician-Scientist, National Medical Research Council (2014)

Research Interests

  • “Big Data” science to build precise risk stratification models, and for automation of radiotherapy and cancer management
  • To use contemporary molecular genomics and sequencing techniques to derive novel prognostic and predictive biomarkers of tumour radio resistance
  • Develop novel phase II and III clinical trials in nasopharyngeal (NPC) and prostate cancers


  • Iyer NG, Chua ML. Multidisciplinary team meetings – challenges of implementation science. Nat Rev Clin Oncol 2019; 16(4): 205-6.
  • Chua ML, et al. Letter in reply: SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan. JAMA Oncol 2020; DOI: 10.1001/jamaoncol.2020.0980
  • Yu J, Ouyang W, Chua ML, et al. SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan. JAMA Oncol 2020; DOI: 10.1001/jamaoncol.2020.0980
  • Glicksman RM, Tjong MC, Neves-Junior WF, Spratt DE, Chua KC, Mansouri A, Chua ML, et al. Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review and Synthesis for the Modern Oncologist. JAMA Oncol 2020; DOI: 10.1001/jamaoncol.2019.5351
  • Liu X, Zhang Y, Tang LL, Le QT, Chua ML, et al. The 10-year Landscape of Radiotherapy vs Non-Radiotherapy Oncology Clinical Trials in JAMA Oncol 2018; 4(8): 1073-9.
  • Chua ML, Lo W, Pintilie M, et al. A Prostate Cancer “Nimbosus”: Genomic instability and SChLAP1 dysregulation underpins aggression of intraductal and cribriform sub-pathologies. Eur Urol 2017; 72(5): 665-74. (Platinum Priority and Cover Page of Issue)
  • Chua ML, van der Kwast TH, Bristow RG. Intraductal carcinoma of the prostate gland: Anonymous to Ominous. Eur Urol 2017; 72(4): 496-8.
  • Lalonde E, Alkallas R, Chua ML, et al. Translating a prognostic DNA genomic classifier into the clinic: retrospective validation in 563 localized prostate tumours. Eur Urol 2017; 72(1): 22-31.
  • Guo Y-M, Chen J-R, Feng Y-C, Chua ML, et al. Germline polymorphisms and length of survival of nasopharyngeal carcinoma: An exome-wide association study in multiple cohorts. Adv Sci (Weinh) 2020; 7(10): 1903727.
  • Zhao C, Miao JJ, Shen GZ, Li JG, Shi M, Zhang N, Hu GQ, Chen XZ, Hu XF, Wu SX, Chen JX, Shao XF, Wang L, Han F, Mai HQ, Chua ML, et al. Anti-epidermal growth factor receptor monoclonal antibody combined with cisplatin and 5-Fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, Phase II clinical trial. Ann Oncol 2019; 30(4): 637-43.

Research Trials